Previous 10 | Next 10 |
Aptorum Group (APM) -35% after pricing share and warrant offering.Adial Pharmaceuticals (ADIL) -23%.FuelCell Energy (FCEL) -14% after pricing equity offering.PEDEVCO (PED) -12%.Urban One (UONE) -12%.Greenpro Capital (GRNQ) -12%.Piedmont Lithium (PLL) -9%.Westwater Resource...
FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced that Dr. David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon G...
Progressing planned pre-clinical testing for innovative allogeneic MSC-based cellular therapy for both COVID-19 and aGVHD FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based ...
Thinly traded micro cap Avalon GloboCare ( AVCO +15.9% ) jumps on a healthy 60x surge in volume in reaction to its agreement with Cellex to distribute the latter's rapid COVID-19 antibody blood test in the U.S., approved for emergency use during the pandemic. More news on: Avalon Globo...
FREEHOLD, N.J., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced that the Company has entered into a commercialization partnership agreement with No...
Avalon GloboCare (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, has expanded and filed two provisional patents with the U.S. Patent and Trademark Office. A result of Avalon’s AVA-Trap(TM) therapeutic program, the patents outline composit...
Expands and files two USPTO provisional patent applications jointly with the Massachusetts Institute of Technology (MIT) Media Lab to develop a cytokine-specific blood purification system based on Avalon’s proprietary AVA-Trap ™ technology Reflects advancements to...
Adam Smith (1723-1790) was not who you think he was. I'm talking about the original Adam Smith who wrote The Wealth of Nations (1776) and spent most of his life in Edinburgh, Scotland. The more recent "Adam Smith" - nom de plume of the late George Goodman who wrote The Money Game (1967) - ...
Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia; Achieved 90% Complete Remission (CR) Rate with Minimum Toxicity or Adverse Side Effects Successfully Completed Pre-Clinical Research On AVA-011, Includ...
Avalon GloboCare ( AVCO -6.4% ) completes Phase I first-in-human clinical study of its lead Chimeric Antigen Receptor (CAR) T-cell therapy candidate, AVA-001. More news on: Avalon GloboCare Corp., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Avalon GloboCare Corp. Company Name:
AVCO Stock Symbol:
NASDAQ Market:
Company to Begin Trading under New Symbol “ALBT” on November 10, 2022 Symbol Change Better Reflects Avalon’s New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon...
Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a ...
Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ: AVCO) , a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Ch...